TY - JOUR AU - Urbini, Milena PY - 2019 TI - Avapritinib: preclinical studies of a promising novel therapeutic option for gastrointestinal stromal tumors JF - Gastrointestinal Stromal Tumor; Vol 2 (February 2019): Gastrointestinal Stromal Tumor Y2 - 2019 KW - N2 - Gastrointestinal stromal tumors (GISTs) represent the most common mesenchymal tumor of the gastrointestinal tract (80%), with an annual incidence of 10–15 cases per million people (1). GISTs have become a paradigm for the use of molecular diagnostics and targeted therapy, since its molecular classification is able to predict treatment response. Most GISTs are driven by activating mutations in KIT (70–80% of cases) or PDGFRA (10%) receptor tyrosine kinases. This discovery represents the rationale of the efficacy of target therapies efficacy using small molecule tyrosine kinase inhibitors (TKIs) for this malignancy (1,2). UR - https://gist.amegroups.org/article/view/27016